The Hike Came
Off the Table.
Week of August 17 — LYB · DBVT · GWRE
July CPI landed right on consensus and September hold odds jumped to ~62–64%. Into the relief: a deep-value cyclical, a binary biotech catalyst, and a quality compounder that has already run.
July CPI landed on target, and September cooled
The July CPI arrived August 12 almost exactly where economists expected: headline +0.1% on the month, 3.4% annual, core +0.2% and 2.5% annual. Both annual readings eased a tenth from June, and all four matched the Dow Jones consensus — a second consecutive benign print.
Odds of a September hike fell to roughly 38%, with a hold now ~62–64%, up from about 52% a day earlier. Energy fell another 1.5% after June's 5.7% drop (though still +14.7% year-over-year), and — less comfortably — July payrolls showed the economy shedding 23,000 jobs. A weak labor market makes tightening far harder to justify.
The hawkish pressure that dominated our last two issues has eased — but this is not an all-clear. Inflation is still well above the 2% target, shelter accounted for about two-thirds of the headline increase, and July PCE, August payrolls and August CPI all land before the September 15–16 FOMC.
So the list spans three different kinds of trade, not three versions of one: a deep-value industrial cyclical at a possible cycle peak, a pre-revenue biotech facing a binary regulatory event, and a quality compounder we flagged two weeks ago that has already moved. None reports during the coming week.
The deep-value cyclical
LYB carries the highest frequency here at 87.5% and a solid 7.13 profit factor, though its 68.5% annualized return is the most modest of the three. A dependable, unspectacular profile — which suits the name.
LyondellBasell is one of the world's largest chemical and plastics manufacturers. The July 31 quarter was spectacular: adjusted EPS of $4.30 against a $3.42 consensus, EBITDA of $2.1B — more than triple Q1 — at a 23% margin on record polyethylene price increases, with free cash flow growth up 178%. Analysts now model ~$8.73 non-GAAP EPS for 2026, up over 400% from $1.70.
Those records exist because the Middle East war steepened the global cost curve for petrochemicals — management said so directly — handing LYB's cost-advantaged US production a windfall. War premiums fade. JPMorgan upgraded to Overweight at $80 while noting plainly that Lyondell is earning above its normalized earnings level. The street is split hard: Goldman $62 (Sell) and BofA $48, versus Morgan Stanley $72 and JPMorgan $80 (both Overweight).
In February 2026 LYB cut its quarterly dividend to $0.69 — a reduction of $0.68, roughly half. The current $2.76 annual rate yields ~4.7%, and on August 14 the board declared the next $0.69 payment for August 31, ex-dividend August 24 — inside this week's window. Income readers should size that yield knowing the payout was already halved once this year.
No earnings next week — Q2 reported July 31. The dated event is the August 24 ex-dividend date for the $0.69 payment (payable Aug 31).
Benefits from easing rate pressure the usual way — leveraged industrial cyclicals prefer a Fed that has stopped tightening — but its real drivers are petrochemical spreads, natural gas costs and the Middle East. At ~7× forward earnings with a 4.7% yield the value case is real; the question is whether those forward earnings are a peak.
Best frequency on the list, a genuine record quarter, a ~7× forward multiple and an ex-dividend date inside the window. The counterweight is unavoidable: those earnings are war-inflated and above normalized levels, the dividend was already halved in February, and targets run $48 to $80. A cyclical value setup, sized for a cycle that may be peaking.
The binary catalyst
Start with the number that matters most, because it is the whole story. DBVT's 1.95 profit factor is the lowest figure this newsletter has ever put in front of you — below WATT's 3.39 and CRM's 2.37.
In plain English: across this window's history, winning periods have outweighed losers by less than two to one. The 81.82% frequency and 72.73% win rate say the pattern shows up often; the profit factor says that when it fails, it gives back nearly everything the winners earned. This is a low-margin-of-error setup, and position sizing is not optional.
DBV is a clinical-stage French biopharma developing Viaskin, a skin patch delivering epicutaneous immunotherapy to train patients to tolerate food allergies — principally peanut allergy in children. The FDA previously granted Breakthrough Therapy Designation, the pivotal Phase 3 VITESSE trial hit its endpoint, the stock is up ~85% over twelve months, and it joined the Euronext Tech Leaders Index in June.
DBV expects to submit its BLA for the Viaskin Peanut Patch in children aged 4–7 during Q3 2026 — which is to say, now. Pre-filing discussions with the FDA focused on organizing existing data for review efficiency, with no additional data requested. Submission triggers a ~10-month review and a potential 2027 launch. Six analysts cover it with a Buy consensus and a ~$40.73 average target; Cantor, Guggenheim and Citizens have all reiterated Buys.
DBVT is pre-revenue. It lost $98.0M in the first half of 2026 alone, with $174.9M of cash funding operations only into Q3 2027 — and it has already raised up to $306.9M via a private placement with warrants, diluting holders. The BLA has slipped once already, from Q2 into Q3. And the commercial precedent is sobering: competing peanut therapy Palforzia saw notably sluggish uptake. A binary regulatory bet on a ~$950M company, not a diversified business.
No earnings next week — H1 results are out. The live event is the Q3 2026 BLA submission, which could land at any point in the window.
Almost entirely detached from the Fed — no CPI print moves a peanut-allergy patch approval. But small, unprofitable, cash-burning biotechs are among the most sentiment-sensitive assets there are, so easing rate pressure and improved risk appetite are a genuine background tailwind. The swing factor is the FDA, full stop.
A high-frequency window into a specific, near-term catalyst — a Q3 BLA with no outstanding FDA data requests, Breakthrough designation behind it, and targets more than double the price. But the 1.95 profit factor is the weakest we have published, on a pre-revenue, cash-burning, dilutive company. Treat this as a speculation sized to be wrong.
The quality compounder
GWRE brings the highest annualized return on the list at 101.72% — the only triple-digit figure here — and the best win rate at 76.92%, with an 85.71% frequency and 5.95 profit factor. On raw quality of profile, the strongest of the three.
Regular readers will recognize it: we featured Guidewire two weeks ago in the August 3 issue, when enterprise software was being punished and the stock sat near $153. It is the dominant platform for the global P&C insurance industry — PolicyCenter, ClaimCenter and BillingCenter run insurers' core operations — deep into a high-margin cloud transition, with 27% revenue growth, ARR up 19% to $1.15B, raised guidance and a $500M buyback.
The stock has already climbed to roughly $175 — up about 14% from where we flagged it. The thesis worked, and quickly. The setup is still constructive: Piper Sandler initiated at Overweight on August 10, Stifel reiterated Buy on August 11, and the average target sits near $201 against a $137–$258 range. But the easy discount is gone — you are buying this after a 14% move, not before it.
Fiscal Q4 expected around September 3, 2026 (est., after close) — after this week's window opens, not during it. Watch ARR growth and FY27 guidance.
The most valuation-sensitive name here — a premium multiple on a long-duration grower — which is precisely why the softer CPI and receding September hike help it most of the three. The franchise is genuinely sticky: insurers don't rip out core policy and claims systems easily. The risks are that rich multiple and the unresolved AI-versus-seat-based-software debate.
Best annualized return and win rate here, attached to the stickiest business — and the softer print helps its premium multiple more than anything else on the list. The honest caveat: up ~14% since we featured it August 3, so the entry is materially worse. Still below a ~$201 average target, with fresh Overweight and Buy coverage.
The three setups, side by side
| Ticker | Frequency | Profit Factor | Ann. Return | Annual Win % | Catalyst |
|---|---|---|---|---|---|
| LYBLyondellBasell | 87.5% | 7.13 | 68.5% | 73.33% | Ex-dividend Aug 24 |
| DBVTDBV Technologies | 81.82% | 1.95 | 73.34% | 72.73% | Q3 BLA submission |
| GWREGuidewire Software | 85.71% | 5.95 | 101.72% | 76.92% | Earnings ~Sep 3 |
The Big Picture
Three names, three genuinely different engines — chosen so the week does not depend on a single thesis being right.
Notice how differently the same macro reads across them. The receding September hike is a direct tailwind for GWRE's premium multiple, a mild positive for a leveraged cyclical like LYB, and largely irrelevant to DBVT, whose fate rests with the FDA rather than the Fed. Meanwhile the softening labor market that helped cool those hike odds is itself a warning for industrial demand — which is LYB's risk, not Guidewire's. Spreading exposure across a cycle trade, a catalyst trade and a quality compounder is how you keep one wrong assumption from deciding the whole week.
The goal is never to predict the week perfectly. Seasonality gives you the roadmap; the data and catalyst calendars give you the events; the Fed backdrop tells you which risks to size carefully. From there: watch the price action, respect your stops, and refuse to let emotion decide.
Sign Up to View Full Trade DetailsSuper Seasonal Trade Desk
